tbuckley/cabot-search huggingface dataset:
Blood Test Predicted Risk of Future Heart Attacks
Authors: Emily Harris
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patient-Reported Outcomes and Mortality in Cutaneous Chronic Graft-vs-Host Disease
Authors: Emily Baumrin, Daniel B. Shin, Nandita Mitra, Joseph Pidala, Najla El Jurdi, Stephanie J. Lee, Alison W. Loren, Joel M. Gelfand
Journal: JAMA Dermatology (2024)

Chronic graft-vs-host disease (GVHD) is associated with impaired quality of life and symptom burden. The independent association of skin involvement with patient-reported outcomes (PROs) and their utility as a clinical prognostic marker remain unknown. Identification of patients with cutaneous chronic GVHD and impaired PROs could assist in initial risk stratification and treatment selection.
Molecular Profiling and the Impact of Treatment on Outcomes in Adenoid Cystic Carcinoma Type I and II
Authors: Glenn J. Hanna, Punita Grover, Andrew Elliott, Julie McGrath, Joanne Xiu, Ammar Sukari, Jennifer M. Johnson, Trisha Wise-Draper
Journal: Clinical Cancer Research (2024)

Abstract Purpose: Adenoid cystic carcinoma (ACC) is an uncommon salivary gland cancer with no approved therapies available to treat advanced, incurable disease. Recent molecular profiling efforts have identified two important subtypes: the more aggressive ACC-I is characterized by Notch pathway alterations and MYC amplification whereas ACC-II demonstrates a more indolent phenotype and TP63 overexpression. Experimental Design: This retrospective observational cohort study involved de-identified samples from 438 patients with ACC with tumor samples sent for commercially-available molecular profiling (Caris Life Sciences). Next-generation whole-exome and whole-transcriptomic sequencing was performed on primary and metastatic samples. Immunostaining for PD-L1 and RNA deconvolution (quanTIseq) was used to explore the tumor immune microenvironment (TME). Real-world clinical and survival outcome metrics were extracted from insurance claims data. Results: MYC expression was 1.61-fold higher (39.8 vs. 24.7; P &amp;lt; 0.0001) among NOTCH1-mutant ACC-I tumors, whereas MYB/L1 fusion rates were similar among ACC-I/II. The median B-cell fraction in the TME was higher among ACC-II (7.1% vs. 5.8%; P &amp;lt; 0.01), although infiltrating T cells subsets were low among either ACC subgroup (both &amp;lt;1%). When pooling systemic treatment categories, ACC-I patients had worse outcomes with available therapies (HR, 3.06; 95% confidence interval, 1.65–5.68; P &amp;lt; 0.01), with no significant difference in overall survival between ACC-I/II based on chemotherapy or VEGFR tyrosine kinase inhibitor exposure in smaller subsets. Conclusions: We confirmed the previously reported associations with MYC and TP63 in the prognostically relevant subgroups of ACC-I and -II, respectively, and report immunologic differences among these subtypes. Survival outcomes are comparatively worse in ACC-I regardless of treatment type.
Knowledge, Preference, and Adverse Effects of Xylazine Among Adults in Substance Use Treatment
Authors: Martin Hochheimer, Justin C. Strickland, Jill A. Rabinowitz, Jennifer D. Ellis, Kelly E. Dunn, Andrew S. Huhn
Journal: JAMA Network Open (2024)

This cross-sectional study evaluates aspects of xylazine adulteration of opioids among individuals entering substance use disorder treatment.
Pathomics Signature for Prognosis and Chemotherapy Benefits in Stage III Colon Cancer
Authors: Wei Jiang, Huaiming Wang, Xiaoyu Dong, Xian Yu, Yandong Zhao, Dexin Chen, Botao Yan, Jiaxin Cheng, Shuangmu Zhuo, Hui Wang, Jun Yan
Journal: JAMA Surgery (2024)

Importance The current TNM staging system may not provide adequate information for prognostic purposes and to assess the potential benefits of chemotherapy for patients with stage III colon cancer. Objective To develop and validate a pathomics signature to estimate prognosis and benefit from chemotherapy using hematoxylin-eosin (H-E)–stained slides. Design, Setting, and Participants This retrospective prognostic study used data from consecutive patients with histologically confirmed stage III colon cancer at 2 medical centers between January 2012 and December 2015. A total of 114 pathomics features were extracted from digital H-E–stained images from Nanfang Hospital of Southern Medical University, Guangzhou, China, and a pathomics signature was constructed using a least absolute shrinkage and selection operator Cox regression model in the training cohort. The associations of the pathomics signature with disease-free survival (DFS) and overall survival (OS) were evaluated. Patients at the Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, formed the validation cohort. Data analysis was conducted from September 2022 to March 2023. Main Outcomes and Measures The prognostic accuracy of the pathomics signature as well as its association with chemotherapy response were evaluated. Results This study included 785 patients (mean [SD] age, 62.7 [11.1] years; 437 [55.7%] male). A pathomics signature was constructed based on 4 features. Multivariable analysis revealed that the pathomics signature was an independent factor associated with DFS (hazard ratio [HR], 2.46 [95% CI, 2.89-4.13]; P &amp;amp;lt; .001) and OS (HR, 2.78 [95% CI, 2.34-3.31]; P &amp;amp;lt; .001) in the training cohort. Incorporating the pathomics signature into pathomics nomograms resulted in better performance for the estimation of prognosis than the traditional model in a concordance index comparison in the training cohort (DFS: HR, 0.88 [95% CI, 0.86-0.89] vs HR, 0.73 [95% CI, 0.71-0.75]; P &amp;amp;lt; .001; OS: HR, 0.85 [95% CI, 0.84-0.86] vs HR, 0.74 [95% CI, 0.72-0.76]; P &amp;amp;lt; .001) and validation cohort (DFS: HR, 0.83 [95% CI, 0.82-0.85] vs HR, 0.70 [95% CI, 0.67-0.72]; P &amp;amp;lt; .001; OS: HR, 0.80 [95% CI, 0.78-0.82] vs HR, 0.69 [0.67-0.72]; P &amp;amp;lt; .001). Further analysis revealed that patients with a low pathomics signature were more likely to benefit from chemotherapy (eg, combined cohort: DFS: HR, 0.44 [95% CI, 0.28-0.69]; P = .001; OS: HR, 0.43 [95% CI, 0.29-0.64]; P &amp;amp;lt; .001). Conclusions and Relevance These findings suggest that a pathomics signature could help identify patients most likely to benefit from chemotherapy in stage III colon cancer.
Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types
Authors: Patrick G. Pilié, Virginia Giuliani, Wei-Lien Wang, Daniel J. McGrail, Christopher A. Bristow, Natalie Y.L. Ngoi, Keith Kyewalabye, Khalida M. Wani, Hung Le, Erick Campbell, Nora S. Sanchez, Dong Yang, Jinesh S. Gheeya, Rohit Vivek Goswamy, Vijaykumar Holla, Kenna Rael Shaw, Funda Meric-Bernstam, Chiu-Yi Liu, XiaoYan Ma, Ningping Feng, Annette A. Machado, Jennifer P. Bardenhagen, Christopher P. Vellano, Joseph R. Marszalek, Eeson Rajendra, Desiree Piscitello, Timothy I. Johnson, Maria Likhatcheva, Elias Elinati, Jayesh Majithiya, Joana Neves, Vera Grinkevich, Marco Ranzani, Marina Roy Luzarraga, Marie Boursier, Lucy Armstrong, Lerin Geo, Giorgia Lillo, Wai Yiu Tse, Alexander J. Lazar, Scott E. Kopetz, Mary K. Geck Do, Sarah Lively, Michael G. Johnson, Helen M.R. Robinson, Graeme C.M. Smith, Christopher L. Carroll, M. Emilia Di Francesco, Philip Jones, Timothy P. Heffernan, Timothy A. Yap
Journal: Clinical Cancer Research (2024)

Mutations in the ATM gene are common in multiple cancers, but clinical studies of therapies targeting ATM-aberrant cancers have yielded mixed results. Refinement of ATM loss of function (LOF) as a predictive biomarker of response is urgently needed.
Reticulon 3 deficiency ameliorates post‐myocardial infarction heart failure by alleviating mitochondrial dysfunction and inflammation
Authors: Bingchao Qi, Tiantian Li, Haixia Luo, Lang Hu, Renqian Feng, Di Wang, Tingwei Peng, Gaotong Ren, Dong Guo, Mingchuan Liu, Qiuhe Wang, Mingming Zhang, Yan Li
Journal: MedComm (2024)

Multiple molecular mechanisms are involved in the development of heart failure (HF) after myocardial infarction (MI). However, interventions targeting these pathological processes alone remain clinically ineffective. Therefore, it is essential to identify new therapeutic targets for alleviating cardiac dysfunction after MI. Here, gain- and loss-of-function approaches were used to investigate the role of reticulon 3 (RTN3) in HF after MI. We found that RTN3 was elevated in the myocardium of patients with HF and mice with MI. Cardiomyocyte-specific RTN3 overexpression decreased systolic function in mice under physiological conditions and exacerbated the development of HF induced by MI. Conversely,
The MISSION Act Needs Measurement
Authors: Philip P. Goodney, Aravind S. Ponukumati, Laura E. Newton
Journal: JAMA Surgery (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Spesolimab Response in a Girl With Acrodermatitis Continua of Hallopeau
Authors: Youcong Wang, Li Zhang, Jie Zheng, Xia Li, Lihong Chen
Journal: JAMA Dermatology (2024)

This case report summarizes the treatment of acrodermatitis continua of Hallopeau with spesolimab in a 9-year-old girl.
Telehealth Abortions as Safe and Effective as In-Person Ones
Authors: Emily Harris
Journal: JAMA (2024)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Common Bile Duct Injury in Cholecystectomy
Authors: Eugene O. Dickens
Journal: JAMA Surgery (2024)

To the Editor I read with great interest the article by Kalata et al1 regarding the observation of common bile duct injury (CBDI) in Medicare patients from 2010 through 2019. This retrospective, claims-based research can provide meaningful insight despite the many limitations of such an inquiry.
All That Is Small Is Not a Small-Cell Carcinoma: Thoracic SMARCA4-Deficient Undifferentiated Tumors Masquerading as SCLC
Authors: Natasha Rekhtman
Journal: Clinical Cancer Research (2024)

Summary Small-cell lung carcinoma (SCLC) cell lines have been widely utilized as a preclinical model of this highly aggressive disease. However, since their creation decades ago, novel tumor entities have been defined that might clinicopathologically mimic SCLC, which notably includes thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT). Multiomic reassessment of the presumed SCLC cell lines with high YAP1 expression reveals that nearly all of these tumors represent unsuspected SMARCA4-UT. See related article by Ng et al., p. 1846
Herbal Products‐Powered Thermosensitive Hydrogel with Phototherapy and Microenvironment Reconstruction for Accelerating Multidrug‐Resistant Bacteria‐Infected Wound Healing
Authors: Gang Zhao, Guanghua Lu, Huizhen Fan, Li Wei, Qiang Yu, Ming Li, Hanqing Li, Nuo Yu, Shen Wang, Min Lu
Journal: Advanced Healthcare Materials (2024)

Abstract Wound healing and infection remain significant challenges due to the ineffectiveness against multidrug‐resistant (MDR) bacteria and the complex oxidative wound microenvironments. To address these issues, thymoquinone‐reinforced injectable and thermosensitive TQ@PEG‐PAF‐Cur hydrogels with dual functions of microenvironment reshaping and photodynamic therapy are developed. The hydrogel comprises natural compound thymoquinone (TQ) and poly (ethylene glycol)‐block‐poly (alanine‐co‐phenyl alanine) copolymers (PEG‐PAF) conjugated with natural photosensitizer curcumin (Cur). The incorporation of TQ and Cur reduces the sol‐to‐gel transition temperature of TQ@PEG‐PAF‐Cur to 30°C, compared to PEG‐PAF hydrogel (37°C), due to the formation of strong hydrogen bonding, matching the wound microenvironment temperature. Under blue light excitation, TQ@PEG‐PAF‐Cur generates significant amounts of reactive oxygen species such as H 2 O 2 , 1O 2 , and ·OH, exhibiting rapid and efficient bactericidal capacities against methicillin‐resistant Staphylococcus aureus and broad spectrum β‐lactamases Escherichia coli via photodynamic therapy (PDT). Additionally, Cur effectively inhibits the expressions of proinflammatory cytokines in skin tissue‐forming cells. As a result, the composite hydrogel can rapidly transform into a gel to cover the wound, reshape the wound microenvironment, and accelerate wound healing in vivo. This collaborative antibacterial strategy provides valuable insights to guide the development of multifunctional materials for efficient wound healing.
Endothelial cells drive organ fibrosis in mice by inducing expression of the transcription factor SOX9
Authors: Felix A. Trogisch, Aya Abouissa, Merve Keles, Anne Birke, Manuela Fuhrmann, Gesine M. Dittrich, Nina Weinzierl, Elvira Wink, Julio Cordero, Adel Elsherbiny, Abel Martin-Garrido, Steve Grein, Shruthi Hemanna, Ellen Hofmann, Luka Nicin, Sofia-Iris Bibli, Rannar Airik, Andreas Kispert, Ralf Kist, Sun Quanchao, Sina W. Kürschner, Manuel Winkler, Norbert Gretz, Carolin Mogler, Thomas Korff, Philipp-Sebastian Koch, Stefanie Dimmeler, Gergana Dobreva, Joerg Heineke
Journal: Science Translational Medicine (2024)

Fibrosis is a hallmark of chronic disease. Although fibroblasts are involved, it is unclear to what extent endothelial cells also might contribute. We detected increased expression of the transcription factor Sox9 in endothelial cells in several different mouse fibrosis models. These models included systolic heart failure induced by pressure overload, diastolic heart failure induced by high-fat diet and nitric oxide synthase inhibition, pulmonary fibrosis induced by bleomycin treatment, and liver fibrosis due to a choline-deficient diet. We also observed up-regulation of endothelial SOX9 in cardiac tissue from patients with heart failure. To test whether SOX9 induction was sufficient to cause disease, we generated mice with endothelial cell–specific overexpression of Sox9 , which promoted fibrosis in multiple organs and resulted in signs of heart failure. Endothelial Sox9 deletion prevented fibrosis and organ dysfunction in the two mouse models of heart failure as well as in the lung and liver fibrosis mouse models. Bulk and single-cell RNA sequencing of mouse endothelial cells across multiple vascular beds revealed that SOX9 induced extracellular matrix, growth factor, and inflammatory gene expression, leading to matrix deposition by endothelial cells. Moreover, mouse endothelial cells activated neighboring fibroblasts that then migrated and deposited matrix in response to SOX9, a process partly mediated by the secreted growth factor CCN2, a direct SOX9 target; endothelial cell–specific Sox9 deletion reversed these changes. These findings suggest a role for endothelial SOX9 as a fibrosis-promoting factor in different mouse organs during disease and imply that endothelial cells are an important regulator of fibrosis.
Phase III randomized trial of Thal+ZLD versus ZLD in patients with asymptomatic multiple myeloma – updated results after 18-year follow-up
Authors: Nadine Abdallah, Thomas E. Witzig, Shaji K. Kumar, Martha Q. Lacy, Suzanne R. Hayman, Angela Dispenzieri, Vivek Roy, Morie A. Gertz, P. Leif Bergsagel, S. Vincent Rajkumar
Journal: Leukemia (2024)
Long-term beneficial effect of faecal microbiota transplantation on colonisation of multidrug-resistant bacteria and resistome abundance in patients with recurrent Clostridioides difficile infection
Authors: Sam Nooij, Karuna E. W. Vendrik, Romy D. Zwittink, Quinten R. Ducarmon, Josbert J. Keller, Ed J. Kuijper, Elisabeth M. Terveer
Journal: Genome Medicine (2024)

Multidrug-resistant (MDR) bacteria are a growing global threat, especially in healthcare facilities. Faecal microbiota transplantation (FMT) is an effective prevention strategy for recurrences of Clostridioides difficile infections and can also be useful for other microbiota-related diseases.
Lymphatic endothelial-like cells in the glioblastoma tumor niche drive metabolic alterations that promote stem cell proliferation and survival
Authors: Reilly L Kidwell, Manish K Aghi
Journal: Neuro-Oncology (2024)

Journal Article Corrected proof Lymphatic endothelial-like cells in the glioblastoma tumor niche drive metabolic alterations that promote stem cell proliferation and survival Get access Reilly L Kidwell, Reilly L Kidwell Department of Neurosurgery, University of California San Francisco, San Francisco, California, USA Search for other works by this author on: Oxford Academic PubMed Google Scholar Manish K Aghi Manish K Aghi Department of Neurosurgery, University of California San Francisco, San Francisco, California, USA Corresponding Author: Manish K. Aghi, MD, PhD, Department of Neurosurgery, University of California San Francisco, San Francisco, California, USA (manish.aghi@ucsf.edu). https://orcid.org/0000-0002-2949-2227 Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, noae020, https://doi.org/10.1093/neuonc/noae020 Published: 28 February 2024 Article history Corrected and typeset: 28 February 2024 Published: 28 February 2024
Therapy for Stage IV Non–Small Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline, Version 2023.3
Authors: Ishmael A. Jaiyesimi, Natasha B. Leighl, Nofisat Ismaila, Krishna Alluri, Narjust Florez, Shirish Gadgeel, Gregory Masters, Erin L. Schenk, Bryan J. Schneider, Lecia Sequist, Navneet Singh, Lyudmila Bazhenova, Elizabeth Blanchard, Janet Freeman-Daily, Naoki Furuya, Balazs Halmos, Ibrahim Hanna Azar, Sara Kuruvilla, Michael Mullane, Jarushka Naidoo, Joshua E. Reuss, David R. Spigel, Dwight H. Owen, Jyoti D. Patel
Journal: Journal of Clinical Oncology (2024)

Living guidelines are developed for selected topic areas with rapidly evolving evidence that drives frequent change in recommended clinical practice. Living guidelines are updated on a regular schedule by a standing expert panel that systematically reviews the health literature on a continuous basis, as described in the ASCO Guidelines Methodology Manual . ASCO Living Guidelines follow the ASCO Conflict of Interest Policy Implementation for Clinical Practice Guidelines . Living Guidelines and updates are not intended to substitute for independent professional judgment of the treating provider and do not account for individual variation among patients. See complete disclaimer in Appendix 1 and Appendix 2 for more. Updates are published regularly and can be found at https://ascopubs.org/nsclc-non-da-living-guideline . PURPOSE To provide evidence-based recommendations for patients with stage IV non–small cell lung cancer (NSCLC) without driver alterations. METHODS This ASCO living guideline offers continually updated recommendations based on an ongoing systematic review of randomized clinical trials (RCTs), with the latest time frame spanning February to October 2023. An Expert Panel of medical oncology, pulmonary, community oncology, research methodology, and advocacy experts were convened. The literature search included systematic reviews, meta-analyses, and randomized controlled trials. Outcomes of interest include efficacy and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS This guideline consolidates all previous updates and reflects the body of evidence informing this guideline topic. Ten new RCTs were identified in the latest search of the literature to date. RECOMMENDATIONS Evidence-based recommendations were updated to address first, second, and subsequent treatment options for patients without driver alterations. Additional information is available at www.asco.org/living-guidelines .
Childhood Adenotonsillectomy Does Not Increase the Risk of Being Overweight in Adulthood
Authors: Aviv D. Goldbart, Ran Abuhasira, Adi Shiloh, Jacov Even-Tsur, Ariel Tarasiuk
Journal: American Journal of Respiratory and Critical Care Medicine (2024)

"Childhood Adenotonsillectomy Does Not Increase the Risk of Being Overweight in Adulthood." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.